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Abstract Proglucagon is alternatively processed to glucagon in 
pancreatic a-cells, or to glucagon-like peptide-1 in intestinal 
L cells. Here, the specificity of PC2, the major prohormone 
convertase of a-cells, was examined both in vivo and in vitro. 
Adenovirus-mediated co-expression of proglucagon and PC2 in 
GH4Ci cells resulted in a pattern of processing products very 
similar to that observed in a-cells. Oxyntomodulin, an inter-
mediate in the processing of proglucagon, was quantitatively 
converted to glucagon in vitro by purified recombinant PC2, in 
combination with carboxypeptidase E. It is concluded that PC2 
is able to act alone in the pancreatic pathway of proglucagon 
processing. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The recent discovery of a novel family of mammalian sub-
tilisin-like intracellular endopeptidases, all related to the yeast 
kexin, has shed new light on the molecular mechanisms of 
limited proteolysis associated with the post-translational proc-
essing of secreted proteins and peptides [1-3]. Two members 
of this family, PC2 (SPC2) and PC3 (SPC3, also known as 
PCI), are expressed in neural and endocrine tissues, and are 
active in the regulated secretory pathway of these cells. PC2 
and PC3 have been implicated in the processing of a growing 
number of pro-hormones and pro-neuropeptides [4—17]. Their 
specificities towards various cleavage sites appear to be dis-
tinct, although overlapping, and variations in their levels of 
expression may be responsible for the differential processing 
of a given precursor, as suggested for the processing of proo-
piomelanocortin [18-20]. 
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Proglucagon (PG) presents another interesting example of 
such a differential processing, leading to the alternative secre-
tion of two hormones having opposite biological activities 
(Fig. 1). In mammals, the same precursor is initially synthe-
sized in both a-cells in the islets of Langerhans of the pan-
creas, and endocrine L cells of the intestinal mucosa [21,22]. 
However pancreatic a-cells secrete glucagon, which stimulates 
glycogenolysis and gluconeogenesis in the liver and counter-
balances the action of insulin on the blood glucose level, 
whereas intestinal L cells release upon stimulation a very po-
tent insulinotropic hormone [23,24], recently identified as a 
truncated form of GLP-1 [25]. 
In intestinal L cells, proglucagon processing mainly results 
in the formation of glicentin (PG 1-69), GLP-1, IP-2, GLP-2 
[26,27]. Glicentin is partially cleaved into GRPP (PG 1-30) 
and oxyntomodulin (PG 33-69), but not to glucagon [28]. An 
additional monobasic cleavage at Arg7r, which only occurs in 
the intestine, yields a shortened form of GLP-1, known as 
truncated GLP-1, or tGLP-1 [25]. In contrast, in the pancreas, 
a-cells mainly process proglucagon to glucagon, GRPP, IP-1, 
and the major proglucagon fragment (MPGF) (PG 72-158), a 
10-kDa peptide encompassing the GLP-1, IP-2, and GLP-2 
sequences [29-31]. In addition a small fraction of the MPGF 
is further processed to inactive N-terminally extended GLP-1 
[31]. This differential processing is thought to result from the 
expression of different convertases in a- and L cells. Pancre-
atic a-cells express high levels of PC2 but low levels, if any, of 
PC3 [10,32-34], while intestinal L cells have immunoreactive 
PC3 but not PC2 [35]. Accordingly, several recent reports 
have suggested that PC2 and PC3 are involved in the pancre-
atic and intestinal phenotypes of processing, respectively 
[10,36-41]. 
However, it has also been proposed that PC2 alone would 
be unable to perform all the cleavages required for the proc-
essing of proglucagon to glucagon [39—41]. According to these 
authors, the formation of glucagon in a-cells would require 
an additional as yet unidentified convertase. In particular, 
they reason that PC2 would be unable to perform the cleavage 
at the Lys62-Arg63 site, that is located at the C-terminus 
of glucagon in the precursor and is essential for the produc-
tion of mature active glucagon (see Fig. 1). Here we show 
that purified recombinant PC2 is indeed able to cleave 
this site in oxyntomodulin, and thus converts this peptide 
into glucagon in vitro. Furthermore, we found that the co-
expression of proglucagon and PC2 in GH4C1 cells recon-
stitutes the processing of proglucagon observed in aTCl-6 
and pancreatic a-cells. These results further support the con-
clusion that PC2 is the endoprotease responsible for the proc-
essing of proglucagon to glucagon in the a-cell, and suggest 
that this enzyme is able to act alone in this processing path-
way. 
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2. Materials and methods 
2.1. Cell culture 
GH4C1 cells were obtained from Dr. D.F. Steiner (University 
of Chicago), and were cultured at 37°C in 5% C02-95% air 
with constant humidity, in DMEM complemented with 10% FCS, 
100 U/ml penicillin, and 100 ug/ml streptomycin. 
2.2. Adenovirus constructions and infections 
The preparation of the purified recombinant adenovirus ex-
pressing PC2 (Ad:PC2) was previously reported [42]. In order to 
construct a recombinant adenovirus expressing proglucagon 
(Ad:Glu), a 1-kbp Ddel fragment of Syrian hamster preproglu-
cagon cDNA [43] was subcloned in the plasmid pACCMV.pLpA 
[44]. Recombinant adenovirus expressing proglucagon was obtained 
by homologous recombination in 293 cells, and purified as pre-
viously described [42,44]. Val87 and Leu91 of proglucagon were re-
placed with Met residues by site directed mutagenesis [45], in order 
to improve the sensitivity of the fluorographic detection of the GLP-1 -
containing peptides. The mutated and wild type proglucagons were 
expressed in COS 7 cells and in AtT-20 cells, and their processing was 
assessed by continuous labeling and pulse-chase, respectively. No dif-
ference was observed regarding the levels of expression, the processing 
patterns, and the efficiency of the immunoprecipitations (data not 
shown). 
GH4C1 cells (approximately 5X105 cells) were washed twice with 
prewarmed DMEM and infected with a minimal volume of 90% 
DMEM-10% FCS containing the virus, for 1 h at 37°C. Co-infections 
were carried out by sequential infections with Ad:PC2 at a multi-
plicity of infection of 5, and then with Ad:Glu at a multiphcity of 
infection of 100, separated by a recovery period of 4 h in normal 
growth medium. Following the contact with the virus, the inoculum 
was removed, the cells were washed twice with DMEM, and returned 
to normal growth medium. 
2.3. Immunoblot analysis 
Infected and control cells were extracted 24 h after infection. The 
proteins in the extracts were separated by SDS-PAGE and transferred 
to nitrocellulose membrane as described [32]. Immunodetection was 
performed with an enhanced chemiluminescence detection kit from 
Amersham (Amersham, Bucks., U.K.). Antibody dilutions and incu-
bations were performed as previously described [32]. 
2.4. Metabolic labeling and immunoprecipitations 
Infected and control cells were labeled with 0.1 mCi of [35S]Met 
in 0.25 ml of Met-deficient medium for 30 min, and chased for 2 h 
in 0.5 ml of medium containing 1 mM Met. Pulse-chase experi-
ments and immunoprecipitations were as described previously [10]. 
The monoclonal antibody GluOOl (from Novo-Nordisk) and the 
GLP-1 antiserum 2135 (generously provided by Dr. J J . Hoist, 
Panum Institute, Copenhagen), that were used for the immuno-
precipitations, recognize N- and/or C-terminally extended forms 
of these peptides. Immunoprecipitates were analyzed by SDS-
PAGE [46] and fluorography. Molecular weights were deter-
mined by comparison with the co-migration of prestained mark-
ers (Biorad), complemented with 125I-labeled GLP-l-(l-37), and 
125I-labeled glucagon, as 4-kDa, 3.4-kDa markers, respectively. 
2.5. In vitro conversion of oxyntomodulin to glucagon 
Five micrograms of synthetic human oxyntomodulin (from Pen-
insula Laboratories) were incubated with 1 |xg of purified recom-
binant PC2 (kind gift from Dr. I. Lindberg, Louisiana State Uni-
versity, New Orleans) and 0.25 ug of purified recombinant CPE 
(generously provided by Dr. L.D. Fricker, Albert Einstein College 
of Medicine, New York), or with CPE alone, in 0.1 M sodium ace-
tate buffer, pH 5.0 containing 10 mM CaCl2, 10 |xM dithiothrei-
tol, 0.05% bovine serum albumin, and 20 uM each of TPCK and 
TLCK. After a 4-h incubation period at 37°C, samples were 
frozen until HPLC analysis. HPLC was performed in a Vydac Ci8 
column with a linear gradient of acetonitrile (0-60% over 60 min) in 
trifluoroacetic acid (0.05%). Synthetic glucagon and oxyntomodulin 
standards were chromatographed separately to determine their elution 
time. 
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3. Results 
3.1. Processing of proglucagon in GH4Ct cells 
co-expressing PC2 
In order to study PC2-mediated processing of proglucagon 
in an appropriate cellular environment, proglucagon and PC2 
were co-expressed with recombinant replication-defective ad-
enovirus vectors in GH4C1 cells. This rat pituitary derived cell 
line, was chosen, because it had previously been reported that 
they possess a regulated secretory pathway formed by classical 
dense core granules [47], without expressing detectable levels 
of the convertases PC2 or PC3 , usually associated with the 
regulated secretory pathway of endocrine cells [3]. Accord-
ingly, they do not efficiently process transfected proglucagon 
[36,48]. Using an El-deleted adenovirus as a vector allowed 
the overexpression of the transgene, with reduced expression 
of the viral proteins, thus preventing the cell toxicity associ-
ated with the viral replication [42,44]. Following infection 
with Ad :PC2 , the expression of PC2 was assessed by immu-
noblot analysis (Fig. 2). Uninfected cells and cells infected 
with A d : G l u alone were devoid of detectable PC2-immuno-
reactive material, whereas cells co-infected with A d : G l u and 
A d : P C 2 displayed a strong signal for the 75-kDa pro-PC2 
and a weaker signal for the 68-kDa mature form of PC2. 
This pat tern has regularly been observed when PC2 is ex-
pressed without 7B2, its specific chaperone [49-51]. Using 
lower m.o.i. did not significatively change the relative 
amounts of pro and mature forms [42]. 
The processing of proglucagon was studied by pulse-chase 
experiments followed by immunoprecipitation of glucagon-
and GLP-1-containing peptides with specific antibodies. After 
SDS-PAGE, and fluorography Fig. 3 shows that , in the ab-
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Fig. 1. Schematic representation of proglucagon and its processing 
products in the pancreas and the intestine. Homologous sequences 
are shown as shaded areas. Monobasic and dibasic sites that are 
cleaved by the convertases are shown as black bars and numbered 
from 1 to 6. A pair of arginines, that is present in the glucagon 
moiety and is not cleaved in the pancreas nor in the intestine, is 
also represented. Note that about 10 to 20% of the MPGF is con-
verted in the pancreas to a 4-kDa N-terminally extended form of 
GLP-1, which is not found in the intestine. GRPP, glicentin-related 
pancreatic polypeptide; MPGF, major proglucagon fragment; GLP, 
glucagon-like pep tide; tGLP-1, truncated GLP-1; IP, intervening 
peptide; OXYNTO, oxyntomodulin. Sites: 1, Lys31-Arg32; 2, Lys62-
Arg63; 3, Lys™-Arg71; 4, Arg77; 5, Arg109-Arg110; 6, Arg124-Arg125. 
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Fig. 2. Immunoblot analysis of PC2 expression in GH4C1 cells fol-
lowing infection with adenovirus vectors. GH4C1 cells were mock 
infected (lane 1), infected with Ad:Glu at m.o.i. = 100 (lane 2), or 
co-infected with Ad:Glu at m.o.i. = 100 and Ad:PC2 at m.o.i. = 5 
(lane 3). Cells were extracted 24 h later, and the extracts submitted 
to SDS-PAGE and transferred to a nitrocellulose membrane. The 
blot was developed with a mixture of anti-actin and anti-PC2 anti-
sera. The migration of molecular weight markers is indicated. 
sence of co-expressed PC2, the 19-kDa proglucagon was the 
major glucagon- and/or GLP-1-containing peptide that had 
accumulated in the cells after 2 h of chase. Lower amounts 
of a 9-kDa glucagon-containing peptide and of a 8-kDa 
GLP-1-containing peptide were also detected. These two pep-
tides were previously identified as glicentin and MPGF, re-
spectively [10]. These results indicated that proglucagon was 
partly cleaved at the interdomain site Lys70-Arg71 by endog-
enous convertases of GH4C1 cells, as previously observed with 
a vaccinia virus vector [36]. Very low amounts of a truncated 
form of MPGF with an apparent molecular mass of about 
7 kDa, and of 3.4-kDa GLP-1 were also detected. In contrast, 
when PC2 was co-expressed, levels of proglucagon and glicen-
tin were markedly lowered, and amounts of MPGF were in-
creased. Two other peptides were immunoprecipitated, that 
were not detected when PC2 was omitted: a 3.4-kDa gluca-
gon-containing peptide and a 4-kDa peptide precipitated by 
the GLP-1 antiserum, that were previously identified as being 
mature glucagon and GLP-l-(l-36 amide), respectively [10]. It 
should be noted that glucagon contains only one methionine 
residue, as opposed to the four present in the mutated pro-
glucagon used during this study; the molar ratio of glucagon 
relative to proglucagon is thus underestimated by a factor of 
four. After overexposure, lower levels of a 4.5-kDa glucagon-
containing peptide were also detected. This compound was 
previously identified as oxyntomodulin and was shown to be 
an intermediate in the processing of proglucagon to glucagon 
in ocTCl-6 cells [10]. These results indicated that, when co-
expressed in GH4C1 cells, PC2 processed proglucagon mainly 
to glucagon and MPGF, with partial conversion of MPGF 
to N-terminally extended GLP-1, a set of peptides seen in 
ceTCl-6 cells and in pancreatic a-cells in very similar propor-
tions [10,31]. Interestingly, using a higher multiplicity of in-
fection for Ad:PC2 resulted in higher levels of PC2, and con-
sequently in a higher enzyme to substrate ratio, but did not 
significantly change the relative proportions of glucagon, 
MPGF, and GLP-1 (data not shown). 
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Fig. 3. PC2-mediated processing of proglucagon in GH4C1 cells co-infected with adenovirus vectors. GH4Q cells were mock infected (lanes 1 
and 4), infected with Ad:Glu at m.o.i. = 100 (lanes 2 and 5), or co-infected with Ad:Glu at m.o.i. = 100 and Ad:PC2 at m.o.i. = 5 (lanes 3 and 
6). The day after, cells were labeled for 30 min with [35S]Met and chased for 2 h. Cells were lysed and lysates were immunoprecipitated with 
an anti-glucagon antibody (lanes 1 to 3), or an anti-GLP-1 antiserum (lanes 4 to 6). Immunoprecipitated material was analyzed by SDS-PAGE 
and fluorography. The migration of the molecular weight markers is indicated. PRO, proglucagon; GLI, glicentin; GLU, glucagon; MPGF, 
major proglucagon fragment; GLP-1, glucagon-like peptide-1. 
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Fig. 4. In vitro conversion of oxyntomodulin to glucagon by re-
combinant purified PC2 and CPE. Oxyntomodulin (5 |xg) was incu-
bated with CPE (0.25 ug) (A), or with both PC2 (1 ug) and CPE 
(0.25 ug) (B) in sodium acetate buffer 0.1 M, pH 5.0 at 37°C for 
4 h. Peptides present at the end of the incubation were identified by 
their elution time in HPLC. Elution times of synthetic oxyntomodu-
lin (OXT), and glucagon (GLU) are indicated by arrows. 
3.2. In vitro conversion of oxyntomodulin to glucagon by 
recombinant PC2 
The data above show that PC2 is important for the proc-
essing of proglucagon to glucagon in vivo. This finding is 
consistent with a previous report indicating that immunopre-
cipitated PC2 is indeed able to cleave proglucagon at both 
Lys31-Arg32 and Lys70-Argn sites in vitro [39], two cleavages 
involved in the processing of proglucagon to glucagon. To 
directly determine whether PC2 could cleave at Lys62-Arg63, 
which is the third cleavage essential for the formation of glu-
cagon (see Fig. 1), synthetic oxyntomodulin was incubated 
with purified recombinant PC2 and CPE, followed by separa-
tion of the products by HPLC (Fig. 4). A single peak, exhib-
iting the same retention time as synthetic glucagon, was ob-
served, indicating the cleavage of oxyntomodulin by PC2 at 
the Lys-Arg site C-terminal to glucagon. Despite a near com-
plete conversion to glucagon, no cleavage occurred at an in-
ternal Arg-Arg pair present in both oxyntomodulin and glu-
cagon, demonstrating the specificity of cleavage. 
4. Discussion 
We have previously proposed that proglucagon is a two-
domain precursor, and that its differential processing can be 
regarded as an alternative processing of its N- or C-terminal 
domains, following an initial cleavage at the interdomain site 
[1]. According to this model, the alternative processing of 
proglucagon would be the result of the actions of different 
convertases, with distinct specificities, in a-cells and in L cells. 
Evidence has been presented that PC2 is the convertase re-
sponsible for the pancreatic processing [10], and that PC3 is 
involved in the intestinal one [36,41]. This hypothesis is in 
agreement with the known expression of PC2, and lack of 
PC3, in pancreatic a-cells [10,32-34], and the immunological 
detection of PC3, but not PC2, in intestinal L cells [35]. 
However, the actual role of PC2 has been questioned [39-
41]. It has been suggested that other convertases, such as PC3 
or PC6A, may participate to this processing in addition to 
PC2. We now show that the co-expression of PC2 and pro-
glucagon results in the formation of the processing products 
that are normally found in pancreatic a-cells and in aTCl-6 
cells, including the partial cleavage of MPGF at the Arg109-
Arg110 site, that liberates limited amounts of 4-kDa GLP-1 
[10,31]. Interestingly, the relative proportions between the 
processing products were remarkably similar to the ones nat-
urally found in pancreatic a-cells and in aTCl-6 cells. This 
further supports the conclusion that PC2 alone is the endo-
protease responsible for the a-cell processing pathway. These 
results corroborate our previous report showing that the ex-
pression of proglucagon in AtT-20 cells stably transfected 
with PC2 resulted in the formation of glucagon [36]. However, 
similar co-expression experiments with vaccinia virus vectors 
did not allow proglucagon to be processed to glucagon, but 
only to glicentin [41], suggesting that the use of a vaccinia 
vector for expressing PC2 did not allow the delivery of high 
amounts of active PC2 to the distal compartment of the regu-
lated secretory pathway, where the conversion of glicentin to 
glucagon is thought to occur. 
One of the major argument presented against the conclu-
sion that PC2 alone is the endoprotease responsible for the 
formation of glucagon was its reported failure to cleave pro-
glucagon at the Lyse2-Arg63 site in vitro [39]. However, in the 
present report, we show that purified recombinant PC2 is in-
deed able to cleave oxyntomodulin at this site. Oxyntomodu-
lin is a natural intermediate in the conversion of proglucagon 
to glucagon. Pulse-chase experiments in aTCl-6 cells have 
demonstrated that proglucagon is initially processed to glicen-
tin following cleavage at the Lys70-Arg71 interdomain site. 
Glicentin is then cleaved either at the Lys62-Arg63, or at the 
Lys31-Arg32 sites, to generate proglucagon-(l-61) and oxynto-
modulin intermediates, respectively. Finally these secondary 
intermediates are cleaved at the Lys31-Arg32 and, Lys62-
Arg63, respectively, and this gives rise to mature glucagon 
[10]. Thus, the production of glucagon requires three succes-
sive cleavages, and perhaps the low activity of the PC2 prep-
aration used by Rothenberg et al. [39], which only partially 
cleaved the Lys70-Arg71 and Lys31-Arg32 sites, accounts for its 
failure to cleave the third site in vitro. 
In conclusion, the demonstration that PC2 is the endopro-
tease responsible for the formation of glucagon is now sup-
ported by several convergent lines of evidence: (1) Heterolo-
gous expression of proglucagon in various cell lines allowed 
correlations to be made between glucagon production and 
expression of PC2 [10,36,38]; (2) Expression of PC2 antisense 
RNA in aTCl-6 cells inhibited both PC2 production and 
proglucagon processing concomitantly [10]; (3) Co-expression 
of proglucagon and PC2 in AtT-20 cells [36], or in GH4C1 
cells [this work] resulted in the efficient processing of proglu-
cagon to glucagon, whereas parallel expression of progluca-
gon in control cells only produced very low levels of mature 
glucagon in AtT-20 cells, and no detectable glucagon in 
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G H 4 C i cells; and (4) PC2 is able to cleave in vitro the Lys
3 1-
Arg3 2 , Lys70-Arg71 [39], and Lys6 2-Arg6 3 [this work] sites of 
proglucagon, the cleavage of which leads to the production of 
glucagon in vivo. 
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